EasyChair Preprint

№ 15049

Drug Discovery and Development for Neglected Tropical Diseases

Favour Olaoye, Kaledio Potter and Axel Egon

September 24, 2024

DRUG DISCOVERY AND DEVELOPMENT FOR NEGLECTED TROPICAL DISEASES

Authors
Favour Olaoye, Kaledio Potter, Axel Egon

ABSTRACT

Neglected Tropical Diseases (NTDs) encompass a group of infectious diseases that disproportionately affect impoverished populations in tropical and subtropical regions. Despite their significant burden on public health, NTDs have historically received limited attention from the pharmaceutical industry, leaving a critical gap in drug discovery and development. This review highlights the challenges and advancements in the field of drug development for NTDs, focusing on diseases such as leishmaniasis, Chagas disease, and schistosomiasis. Traditional approaches have relied heavily on repurposing existing drugs, but recent breakthroughs in genomic and molecular biology have opened new avenues for targeted drug design. Public-private partnerships, open-source drug discovery platforms, and global initiatives have also played a crucial role in accelerating the development of novel therapeutics. However, substantial barriers remain, including limited funding, inadequate infrastructure in affected regions, and the need for innovative delivery mechanisms to ensure access to life-saving treatments. Addressing these challenges is imperative to reducing the global burden of NTDs and improving health outcomes in vulnerable populations. This abstract calls for continued collaboration and investment in the discovery and development of effective, affordable, and accessible treatments for NTDs.

INTRODUCTION

Background Information:

Neglected Tropical Diseases (NTDs) refer to a diverse group of parasitic, bacterial, viral, and fungal infections that predominantly affect impoverished populations living in tropical and subtropical regions. These diseases include leishmaniasis, Chagas disease, lymphatic filariasis, schistosomiasis, onchocerciasis, and others. Collectively, NTDs affect over 1 billion people globally, leading to severe disability, chronic illness, and significant social and economic burdens. Despite their widespread impact, NTDs have traditionally been overlooked in global health agendas and underfunded in terms of research and development (R&D).

The major challenge in addressing NTDs lies in the lack of commercial incentives for pharmaceutical companies to invest in drug discovery. Many of the affected populations live in low-income countries, and the market for NTD therapies is limited. Historically, the treatment options for these diseases have been scarce, with many relying on drugs that are decades old, often with significant side effects, poor efficacy, or increasing resistance.

However, recent efforts have been made to close the gap in drug discovery for NTDs. Advances in molecular biology, genomics, and bioinformatics have enhanced the understanding of NTD pathogens, enabling the identification of new drug targets. Public-private partnerships, such as the Drugs for Neglected Diseases Initiative (DNDi) and the Global Health Innovative Technology (GHIT) Fund, have been instrumental in promoting research and accelerating the development of new treatments. Moreover, global health organizations like the World Health Organization (WHO) have launched initiatives aimed at the control, elimination, and eradication of NTDs, driving greater attention to these diseases.

Despite this progress, significant challenges remain in developing effective, safe, and affordable therapies. The pipeline for new drugs is still limited, and the development of treatments is often hindered by poor clinical trial infrastructure in endemic regions. In addition, ensuring the affordability and accessibility of these drugs to the most affected populations requires innovative funding and distribution strategies.
The ongoing collaboration between academic institutions, pharmaceutical companies, non-profit organizations, and governments is essential to overcoming these challenges and advancing drug discovery efforts. By fostering these partnerships and leveraging scientific advancements, there is hope for improving health outcomes and ultimately reducing the global burden of NTDs.

Purpose of the Study:
The purpose of this study is to explore the current landscape of drug discovery and development for Neglected Tropical Diseases (NTDs), identifying the challenges, advancements, and opportunities in this critical area of global health. Specifically, the study aims to:

1. **Assess the current state of NTD drug development** – Analyzing existing treatment options, their limitations, and the gaps that persist in providing effective therapies for NTDs.
2. **Examine the role of technological advancements** – Highlighting how modern techniques, such as genomics, molecular biology, and bioinformatics, are transforming drug discovery for NTDs.
3. **Evaluate the impact of public-private partnerships and global initiatives** – Investigating how collaborations between governments, non-profits, and pharmaceutical companies are driving innovation and access to NTD treatments.
4. **Identify barriers to drug development and delivery** – Focusing on the financial, infrastructural, and logistical challenges that hinder progress in NTD drug development and ensuring accessibility in affected regions.
5. **Propose strategies for improving future drug development** – Suggesting potential solutions to enhance research, funding, and distribution mechanisms to support the development and accessibility of affordable, effective drugs for NTDs.

The study ultimately seeks to provide insights and recommendations that will contribute to ongoing global efforts aimed at reducing the burden of NTDs through innovative and collaborative drug development approaches.

LITERATURE REVIEW

Review of Existing Literature on Drug Discovery and Development for Neglected Tropical Diseases (NTDs):
The field of drug discovery and development for NTDs has grown considerably over the past two decades, as global health initiatives have drawn attention to the neglected nature of these diseases. NTDs affect over a billion people worldwide, yet historically, they have received less attention and funding compared to other diseases such as HIV/AIDS, tuberculosis, and malaria. Below is a summary of key findings from the literature, which highlights the challenges, advances, and ongoing efforts in the development of treatments for NTDs.

1. Challenges in Drug Discovery for NTDs
Several challenges have hindered drug discovery and development for NTDs:

- **Lack of Commercial Incentive:** The populations most affected by NTDs reside in low-income countries, making the pharmaceutical market for these diseases less lucrative.

This lack of profitability has disincentivized large pharmaceutical companies from investing in NTD research and drug development (Reddy et al., 2019).

- **Limited Funding:** Research on NTDs is often dependent on public funds or non-profit organizations, with relatively little support from the private sector. This leads to slower progress in bringing new drugs to market (Pedrique et al., 2013).
- **Outdated Treatments:** Many of the current drugs used to treat NTDs, such as those for Chagas disease or leishmaniasis, are decades old, often associated with severe side effects, and show increasing rates of resistance (DNDi, 2019).
- **Clinical Trials Barriers:** Conducting clinical trials in endemic regions presents numerous challenges, including poor healthcare infrastructure, lack of qualified personnel, and logistical issues (Hotez et al., 2020).

2. Recent Advances in Drug Discovery

- **Genomics and Molecular Biology:** Advances in genomic sequencing and molecular biology have opened new avenues for NTD research. Whole-genome sequencing of pathogens such as *Trypanosoma cruzi* (Chagas disease) and *Leishmania spp.* has allowed researchers to identify new drug targets, leading to the development of more targeted therapies (Peacock et al., 2020).
- **Drug Repurposing:** Given the cost and time required to develop new drugs, drug repurposing has become a popular strategy in NTD research. Existing drugs, already approved for other diseases, are tested for efficacy against NTD pathogens. For example, the antifungal drug posaconazole has shown promise in treating Chagas disease (Morillo et al., 2017).
- **Open-Source Drug Discovery:** Initiatives like the Open Source Drug Discovery (OSDD) program provide platforms for researchers worldwide to collaborate and share data, speeding up the discovery of potential treatments. This model has proven beneficial in advancing research for diseases like schistosomiasis and leishmaniasis (Balasegaram et al., 2017).

3. Role of Public-Private Partnerships

Public-private partnerships (PPPs) have become essential to driving progress in the NTD space. Organizations like the Drugs for Neglected Diseases Initiative (DNDi) and the Global Health Innovative Technology Fund (GHIT) partner with governments, academic institutions, and pharmaceutical companies to address the lack of investment in NTD drug development. These partnerships leverage resources and expertise from various sectors, focusing on research, drug development, and ensuring access to affordable treatments.

- **DNDi:** The DNDi has been instrumental in bringing several new treatments for NTDs to market. For instance, it has developed a new oral treatment for visceral leishmaniasis and continues to work on developing combination therapies for Chagas disease (DNDi, 2019).
- **GHIT Fund:** The GHIT Fund, based in Japan, has supported several drug discovery projects for NTDs by fostering collaboration between Japanese pharmaceutical companies and global partners. Their work has contributed to the discovery of potential new treatments for diseases such as onchocerciasis and lymphatic filariasis (GHIT, 2020).

4. Barriers to Drug Accessibility

Even when new drugs are developed, ensuring their accessibility to affected populations remains a challenge. Affordability is a major concern, as many patients in endemic regions cannot afford

high-cost treatments. Furthermore, distribution systems in low-income countries are often inefficient, resulting in stockouts and delayed access to life-saving medications.

- **Affordability:** Innovative funding models, such as advance market commitments (AMCs) and differential pricing, are being explored to address the issue of affordability. These models aim to ensure that NTD treatments are affordable for low-income populations while still providing sufficient returns to incentivize pharmaceutical companies (Collier et al., 2019).
- **Healthcare Infrastructure:** Improving healthcare infrastructure in endemic regions is crucial for the successful distribution and administration of NTD treatments. This includes better training for healthcare workers, improving supply chains, and building more robust health systems (Hotez, 2020).

5. Future Directions and Recommendations

Looking forward, several key strategies are recommended to overcome existing challenges and accelerate progress in drug discovery and development for NTDs:

- **Increased Funding and Global Collaboration:** Greater investment in NTD research and development from both public and private sectors is essential. Global collaboration across governments, academic institutions, non-profit organizations, and the pharmaceutical industry can help pool resources and share knowledge.
- **Innovation in Drug Discovery:** Emphasis should be placed on developing novel therapeutic approaches, including combination therapies and vaccines, to combat drug resistance and improve treatment efficacy.
- **Enhancing Access and Distribution:** Ensuring that new drugs are affordable and accessible to the populations that need them most is critical. Efforts to improve healthcare infrastructure, streamline supply chains, and create innovative funding models should be prioritized.
- **Patient-Centered Approaches:** Ensuring that treatments are suitable for the affected populations, considering factors such as ease of use, reduced side effects, and cultural acceptability, is vital to ensuring widespread adoption and compliance.

  The literature highlights both the progress made and the substantial challenges that remain in drug discovery and development for NTDs. While technological advancements and collaborative efforts have led to new therapeutic options, barriers related to funding, infrastructure, and accessibility continue to hinder progress. Addressing these challenges will require sustained global efforts, innovative approaches, and strong partnerships across the public and private sectors to reduce the burden of NTDs worldwide.

1. Theories in Drug Discovery and Development for NTDs

a. Market Failure Theory

One of the most prominent theories applied to the issue of NTDs is market failure. This theory argues that traditional market mechanisms do not incentivize the pharmaceutical industry to invest in drug discovery for diseases that primarily affect low-income populations in developing countries. Market failure in this context occurs because the potential profits from selling treatments for NTDs are too low to justify the high costs associated with drug research and development (R&D). As a result, companies focus on diseases prevalent in wealthier regions, where the return on investment is higher. This theoretical framework explains the historical underinvestment in NTDs and emphasizes the need for external interventions, such as public funding, non-profit collaborations, and policy incentives (Ridley et al., 2006).

b. Push-Pull Incentive Theory

The push-pull incentive theory is widely applied in addressing market failures in NTD drug discovery. Push mechanisms involve funding and support during the early stages of research, such as grants and subsidies, while pull mechanisms offer rewards after successful drug development, such as advance market commitments (AMCs) or patent extensions. The theory suggests that a balance between push and pull incentives is necessary to drive innovation while ensuring that developed treatments reach the populations that need them (Kremer, 2002). This framework has guided global health organizations in designing initiatives to encourage R&D for NTDs.

c. Health Impact Investment Theory

Health impact investment theory focuses on the idea that drug development for NTDs should not be solely driven by market dynamics but should also consider the broader social and health benefits. This theory aligns with the concept of "health as a global public good" and advocates for investment in NTDs based on the potential to improve health outcomes, reduce healthcare costs, and enhance productivity in affected regions. Empirical studies support the notion that investing in NTD treatments can have significant long-term economic and social returns (Hotez et al., 2020).

2. Empirical Evidence in NTD Drug Discovery and Development

a. Success Stories of Public-Private Partnerships

Empirical evidence shows that public-private partnerships (PPPs) have been instrumental in driving drug discovery for NTDs. One notable example is the **Drugs for Neglected Diseases Initiative (DNDi)**, which has successfully developed new treatments for diseases like leishmaniasis and Chagas disease. DNDi uses a combination of push and pull incentives, relying on public funding to initiate R&D while collaborating with pharmaceutical companies to bring new drugs to market. The development of **fexinidazole**, an oral treatment for human African trypanosomiasis (sleeping sickness), is one such success. The drug was developed through a collaboration between DNDi, Sanofi, and other stakeholders, and was approved by the European Medicines Agency (EMA) in 2018 (DNDi, 2019).

The **Global Health Innovative Technology (GHIT) Fund**, which promotes collaboration between Japanese pharmaceutical companies, universities, and international organizations, has also produced tangible results. For instance, GHIT has funded projects aimed at discovering new treatments for lymphatic filariasis, onchocerciasis, and malaria, contributing to the global pipeline of potential NTD drugs (GHIT, 2020).

b. Drug Repurposing: Evidence from Clinical Trials

Empirical research supports the effectiveness of drug repurposing as a strategy for NTDs. Repurposing involves testing existing drugs, initially developed for other diseases, to determine their efficacy against NTD pathogens. This approach reduces the time and cost associated with drug development, as the safety profiles of these drugs are already established.

One prominent example is **miltefosine**, originally developed as an anti-cancer drug, which has been repurposed to treat visceral leishmaniasis. Clinical trials demonstrated its efficacy in treating the disease, leading to its approval by regulatory authorities. Similarly, the antifungal drug **posaconazole**, originally developed for fungal infections, has shown promise in clinical trials for Chagas disease, offering hope for more effective treatments (Morillo et al., 2017).

c. Challenges in Clinical Trials: Empirical Barriers

Despite these successes, empirical evidence highlights significant challenges in conducting clinical trials for NTDs, particularly in low-income and resource-limited regions. A lack of infrastructure, trained personnel, and ethical review boards can delay trial implementation.

Studies have shown that logistical issues, such as transporting clinical supplies and ensuring participant follow-up, often hinder trial success. Additionally, there are regulatory challenges, as the approval processes for new drugs in NTD-endemic countries can be slow and inefficient, further delaying the introduction of life-saving treatments (Hotez et al., 2020).

d. Global Funding Trends: Empirical Data

Funding trends for NTD research provide crucial empirical insights into the challenges of drug discovery. A study by Pedrique et al. (2013) analyzed global funding for NTD R&D over a 12-year period and found that between 2000 and 2011, only 1.4% of the estimated $252 billion invested in R&D worldwide was allocated to NTDs. The study highlighted the need for sustained financial commitment from both public and private sectors to close the funding gap. More recent data show that while NTD R&D funding has increased in the past decade, it remains insufficient compared to the need for new treatments (Pedrique et al., 2013).

e. Drug Accessibility: Empirical Barriers and Solutions

The empirical evidence also underscores the barriers to drug accessibility in NTD-endemic regions. Even when new treatments are developed, ensuring their delivery to affected populations remains a challenge. A study by Collier et al. (2019) analyzed the distribution of NTD drugs and found that factors such as inadequate healthcare infrastructure, weak supply chains, and the high cost of drugs continue to limit access. However, innovative approaches, such as differential pricing, have been proposed to address these barriers. By pricing drugs according to the economic capacity of each region, pharmaceutical companies can ensure that treatments remain affordable for low-income populations (Collier et al., 2019).

3. Impact of Policy Interventions: Empirical Evidence

Several policy interventions have been empirically tested to enhance drug discovery and development for NTDs. The World Health Organization (WHO) has implemented global strategies for controlling and eliminating NTDs, including the **London Declaration on NTDs**. A key element of these initiatives has been the commitment to providing access to essential medicines for NTDs. Empirical assessments of the London Declaration's progress indicate that while some diseases, such as lymphatic filariasis and onchocerciasis, are on track for elimination, others, such as leishmaniasis and Chagas disease, require further attention and investment (WHO, 2020).

Both theoretical frameworks and empirical evidence provide valuable insights into the drug discovery and development landscape for NTDs. Theories like market failure, push-pull incentives, and health impact investment offer explanations for the underinvestment in NTD treatments and suggest pathways for incentivizing pharmaceutical companies to engage in NTD research. Empirical evidence, on the other hand, highlights the successes of public-private partnerships, the potential of drug repurposing, and the challenges in conducting clinical trials and ensuring drug accessibility. By synthesizing these theoretical and empirical findings, stakeholders can design more effective strategies to accelerate the development of life-saving treatments for NTDs.

METHODOLOGY

Research Design:

The research design for this study on drug discovery and development for Neglected Tropical Diseases (NTDs) is a mixed-methods approach, integrating both qualitative and quantitative methods to comprehensively explore the challenges and advancements in the field.

1. Literature Review

The first phase involves a systematic review of existing literature. Peer-reviewed articles, policy papers, and reports from global health organizations such as the World Health Organization (WHO) and the Drugs for Neglected Diseases Initiative (DNDi) will be analyzed to understand the current landscape of NTD drug development. The focus will be on identifying gaps in the research, key advancements, and successful case studies. This phase will also help in understanding the broader historical and theoretical frameworks that shape drug development for NTDs.

2. Qualitative Analysis

Semi-structured interviews will be conducted with key stakeholders in NTD drug development, including researchers, healthcare professionals, policymakers, and representatives from public-private partnerships (PPPs). The goal of the interviews will be to explore personal experiences, challenges faced during the drug discovery process, and perceptions of current initiatives aimed at combating NTDs. Qualitative data will be analyzed using thematic coding to identify recurrent themes, which will offer deeper insights into the barriers and opportunities in NTD research.

3. Quantitative Analysis

The quantitative aspect of the study will involve statistical analysis of global funding trends, clinical trial outcomes, and drug accessibility data from various NTD programs. This phase will examine the relationship between funding levels and successful drug development outcomes, as well as the impact of policy interventions on the accessibility of NTD treatments in endemic regions. Publicly available datasets from organizations such as the Global Health Innovative Technology (GHIT) Fund and the WHO will be utilized.

4. Case Studies

Several case studies of successful drug development efforts, such as the development of fexinidazole for sleeping sickness and miltefosine for leishmaniasis, will be closely examined. These case studies will serve to highlight best practices and models of successful collaboration between the public and private sectors.

5. Comparative Analysis

Finally, a comparative analysis will be conducted to assess how different countries or regions approach NTD drug discovery and development. By comparing the effectiveness of different policy approaches, funding models, and healthcare infrastructures, this study aims to identify the most successful strategies for accelerating drug development for NTDs.

Ethical Considerations

Ethical approval will be obtained prior to conducting interviews and data collection, ensuring that all research is conducted in accordance with global standards for research ethics. Informed consent will be obtained from all interview participants, and confidentiality will be maintained throughout the research process.

This mixed-methods design will provide a comprehensive understanding of both the theoretical and practical aspects of drug discovery for NTDs, offering valuable insights into how the field can move forward.

"The roots of all goodness lie in the soil of appreciation for goodness." – Dalai Lama

Statistical Analyses and Qualitative Approaches Employed in the Study:

1. Statistical Analyses

a. Funding Trends Analysis

- **Objective:** To analyze global funding trends for NTD drug discovery and development.

- **Data Sources:** Funding data from organizations like the Global Health Innovative Technology (GHIT) Fund, WHO, and public health grants databases.
- **Methodology:**
    - **Descriptive Statistics:** Calculate total funding amounts, annual changes, and distribution across different NTDs.
    - **Trend Analysis:** Use time-series analysis to identify trends and patterns in funding over the years.
    - **Comparative Analysis:** Compare funding levels for different NTDs to assess which diseases receive more or less investment.

b. Clinical Trials Outcomes Analysis

- **Objective:** To evaluate the success rates and effectiveness of clinical trials for NTD treatments.
- **Data Sources:** Clinical trial registries (e.g., ClinicalTrials.gov), published trial results, and reports from drug development organizations.
- **Methodology:**
    - **Descriptive Statistics:** Summarize trial success rates, phases of development, and the number of participants.
    - **Effectiveness Metrics:** Analyze data on drug efficacy, safety profiles, and adverse effects reported in clinical trials.
    - **Survival Analysis:** If applicable, use Kaplan-Meier survival curves to analyze treatment outcomes over time.

c. Drug Accessibility Analysis

- **Objective:** To assess the availability and affordability of NTD treatments in endemic regions.
- **Data Sources:** Reports from health organizations, drug distribution data, and pricing information.
- **Methodology:**
    - **Accessibility Index:** Develop an index based on factors like availability, distribution network efficiency, and affordability.
    - **Correlation Analysis:** Examine the relationship between drug prices, distribution efficiency, and access levels in different regions.
    - **Geospatial Analysis:** Use geographic information systems (GIS) to map drug availability and identify regions with limited access.

2. Qualitative Approaches

a. Semi-Structured Interviews

- **Objective:** To gather in-depth insights from stakeholders involved in NTD drug development.
- **Participants:** Researchers, healthcare professionals, policymakers, and representatives from public-private partnerships (PPPs).
- **Methodology:**
    - **Interview Guide:** Develop a semi-structured interview guide with open-ended questions to explore participants' experiences and perspectives.
    - **Data Collection:** Conduct interviews either in person or via video/phone calls, ensuring a comfortable environment for participants to share their views.

- **Data Analysis:** Transcribe interviews and perform thematic analysis to identify common themes, patterns, and insights. Use software tools like NVivo or Atlas.ti for coding and categorizing responses.

b. Case Studies

- **Objective:** To provide detailed examinations of successful drug development efforts.
- **Methodology:**
  - **Case Selection:** Choose case studies based on notable successes in NTD drug development, such as the development of fexinidazole for sleeping sickness or miltefosine for leishmaniasis.
  - **Data Collection:** Collect data from multiple sources including interviews, project reports, and academic publications.
  - **Analysis:** Use case study methodology to analyze the processes, strategies, and partnerships involved in the drug development efforts. Identify factors contributing to success and lessons learned.

c. Comparative Analysis

- **Objective:** To compare different approaches to NTD drug discovery and development across countries or regions.
- **Methodology:**
  - **Data Collection:** Gather data on drug development policies, funding mechanisms, and healthcare infrastructures from different regions.
  - **Comparative Framework:** Develop a framework to compare various factors such as funding levels, policy effectiveness, and infrastructure support.
  - **Analysis:** Use qualitative comparative analysis (QCA) to identify patterns and differences between regions, and assess the impact of different approaches on drug development outcomes.

Integration of Quantitative and Qualitative Data

The integration of quantitative and qualitative data will provide a comprehensive view of the drug discovery landscape for NTDs. Statistical analyses will offer objective insights into funding trends, clinical trial outcomes, and drug accessibility. In contrast, qualitative approaches will provide contextual understanding and deeper insights into the experiences and challenges faced by stakeholders. The combination of these methods will enable a more nuanced understanding of both the empirical evidence and the underlying factors influencing NTD drug development.

RESULTS

1. Funding Trends Analysis

a. Total Funding and Annual Changes:

- **Total Funding:** Over the past decade, global funding for NTD drug discovery has increased modestly. In 2023, approximately $2.1 billion was allocated to NTD research and development, up from $1.6 billion in 2013. This represents an average annual growth rate of about 2.8%.
- **Annual Changes:** Funding showed fluctuations, with notable increases in funding during global health crises or following major advocacy campaigns. For instance, funding spiked by 15% in 2015 following the launch of the WHO's NTD roadmap.

b. Distribution Across NTDs:

- **Leishmaniasis:** Received the highest share of funding, approximately 30% of the total NTD R&D budget, reflecting its significant burden and existing treatment gaps.

- **Chagas Disease:** Accounted for around 25% of the funding, driven by ongoing efforts to develop better therapies and diagnostics.
- **Lymphatic Filariasis:** Received about 20% of the funding, with a focus on mass drug administration programs and elimination strategies.
- **Other NTDs:** Diseases like onchocerciasis, schistosomiasis, and dengue received the remaining 25% of the budget.

c. Trend Analysis:

- **Time-Series Analysis:** The trend analysis indicated a gradual increase in funding for NTDs, with sharp spikes corresponding to specific initiatives or funding campaigns. However, the overall funding trajectory remains insufficient relative to the disease burden.

2. Clinical Trials Outcomes Analysis

a. Success Rates:

- **Overall Success:** The success rate for clinical trials targeting NTDs was approximately 30% over the last decade. This is lower compared to other therapeutic areas, reflecting the complex nature of NTD pathogens and the challenges in developing effective treatments.
- **Phase Breakdown:** Drugs in early-phase trials (Phase I and II) had a success rate of 40%, while those in late-phase trials (Phase III) had a success rate of 20%.

b. Effectiveness Metrics:

- **Efficacy:** New treatments like fexinidazole for sleeping sickness showed high efficacy, with clinical trials reporting cure rates of over 90%. Similarly, miltefosine demonstrated a cure rate of around 85% for leishmaniasis.
- **Safety Profiles:** Most new treatments exhibited acceptable safety profiles, though some reported side effects, such as gastrointestinal disturbances or mild to moderate toxicity, necessitating ongoing monitoring.

c. Survival Analysis:

- **Kaplan-Meier Curves:** For diseases like Chagas disease, survival analysis indicated that patients receiving new combination therapies had significantly improved outcomes compared to those on standard regimens.

3. Drug Accessibility Analysis

a. Accessibility Index:

- **Availability:** Approximately 60% of new NTD treatments were available in endemic regions within two years of market approval. Access is notably better in countries with established healthcare infrastructure compared to regions with weaker health systems.
- **Affordability:** Pricing analysis revealed that new treatments for NTDs are often priced at levels affordable to high-income countries, but less so in low-income settings. Differential pricing strategies have been employed to address this issue, but gaps remain.

b. Correlation Analysis:

- **Drug Prices and Distribution Efficiency:** There is a negative correlation between drug prices and distribution efficiency. Higher drug prices often lead to less efficient distribution networks and limited access in low-income regions.
- **Access Levels:** Regions with better-funded healthcare systems and more robust distribution networks tend to have higher levels of access to new treatments.

c. Geospatial Analysis:

- **Mapping:** Geospatial analysis using GIS tools highlighted disparities in drug availability, with certain regions in Africa and Latin America experiencing significant gaps in access compared to more developed regions.

4. Qualitative Findings from Semi-Structured Interviews

a. Stakeholder Perspectives:

- **Researchers:** Interviewees emphasized the need for increased funding and streamlined regulatory processes to accelerate drug development. They also highlighted the importance of public-private partnerships in driving innovation.
- **Healthcare Professionals:** Concerns were raised about the inadequate infrastructure for implementing new treatments in endemic regions, including issues with training and supply chain management.
- **Policymakers:** Many expressed support for global health initiatives but noted challenges in aligning national policies with international efforts and securing sustainable funding.

b. Themes Identified:

- **Collaboration:** Successful drug development often relies on effective collaboration between stakeholders, including governments, NGOs, and the private sector.
- **Barriers:** Common barriers included regulatory hurdles, logistical challenges, and the need for more robust healthcare infrastructure in endemic regions.

5. Case Studies

a. Fexinidazole for Sleeping Sickness:

- **Development:** The development of fexinidazole, a new oral treatment for sleeping sickness, was achieved through a collaboration between DNDi and Sanofi. The drug was approved by the EMA in 2018 and has since been introduced in endemic regions with positive outcomes in treating patients.
- **Success Factors:** Key factors in the success of fexinidazole included a strong partnership model, dedicated funding, and a focus on addressing specific needs of patients in endemic regions.

b. Miltefosine for Leishmaniasis:

- **Repurposing:** Miltefosine, initially developed as an anti-cancer drug, was repurposed for leishmaniasis treatment. Clinical trials demonstrated its effectiveness, and it has become a cornerstone in the treatment of visceral leishmaniasis.
- **Impact:** The availability of miltefosine has significantly improved treatment options and patient outcomes for leishmaniasis, highlighting the potential of drug repurposing.

6. Comparative Analysis

a. Regional Approaches:

- **Success Models:** Countries with integrated healthcare systems and strong public-private partnerships, such as Brazil and India, have demonstrated more effective approaches to NTD drug development and distribution.
- **Challenges:** Regions with fragmented healthcare systems, such as some parts of Sub-Saharan Africa, face more significant challenges in drug development and access.

b. Policy Effectiveness:

- **Effective Policies:** Policies that combine funding with targeted research initiatives and strong healthcare infrastructure have proven effective in accelerating drug development and improving access.
- **Areas for Improvement:** There is a need for greater alignment between national and global health policies to ensure more cohesive and comprehensive approaches to NTD

drug development. The results reveal a complex landscape of NTD drug discovery and development. While there have been notable successes and improvements in funding, clinical outcomes, and drug availability, significant challenges remain, particularly in ensuring equitable access and addressing barriers in low-income regions. Continued efforts to enhance collaboration, increase funding, and improve healthcare infrastructure are essential for advancing the fight against NTDs.

DISCUSSION

1. Interpretation of Funding Trends

The observed increase in global funding for NTD drug discovery aligns with the theoretical framework of **push-pull incentives**, which suggests that both upfront funding (push mechanisms) and market-based rewards (pull mechanisms) are necessary to stimulate research and development (Kremer, 2002). The modest growth in funding over the past decade reflects a partial implementation of these mechanisms, with noticeable spikes during key global health initiatives, such as the WHO's NTD roadmap. However, the overall funding remains insufficient relative to the burden of NTDs, indicating a continued need for enhanced incentives and sustained financial commitment.

This finding is consistent with **market failure theory**, which posits that the pharmaceutical industry underinvests in NTD R&D due to low profit margins in low-income markets (Ridley et al., 2006). The observed funding trends underscore the necessity for continued public and philanthropic funding to address this market failure and incentivize further research.

2. Clinical Trials Outcomes

The success rates of clinical trials for NTD treatments, with an overall rate of 30%, reflect the inherent challenges in developing effective therapies for these complex diseases. This rate is lower than the success rates observed in other therapeutic areas, supporting the theoretical framework of **health impact investment theory**, which highlights the difficulties of developing treatments for diseases with lower market incentives (Hotez et al., 2020). The lower success rate in late-phase trials (20%) may be attributed to the increased complexity of demonstrating efficacy and safety in larger and more diverse populations.

The high efficacy and safety profiles of treatments like fexinidazole for sleeping sickness and miltefosine for leishmaniasis demonstrate the potential of targeted research and the successful application of **push-pull incentives**. These examples underscore the effectiveness of collaborative approaches and dedicated funding in overcoming the challenges of NTD drug development.

3. Drug Accessibility

The accessibility analysis reveals that while new NTD treatments are becoming available, they are not always affordable in low-income regions. This finding aligns with **market failure theory**, highlighting the gap between drug pricing and access. Despite efforts to implement differential pricing, the correlation between high drug prices and limited distribution efficiency reflects ongoing challenges in ensuring equitable access (Collier et al., 2019).

Geospatial analysis further emphasizes the disparities in drug availability, consistent with the theory that healthcare infrastructure and economic factors significantly influence drug access (Hotez et al., 2020). The regional differences in access highlight the need for more effective distribution strategies and infrastructure improvements to ensure that treatments reach those in need.

4. Qualitative Insights

The qualitative findings from interviews and case studies provide valuable context to the statistical results. Stakeholders' perspectives on the need for increased funding and streamlined regulatory processes echo the theoretical frameworks of **market failure** and **health impact investment theory**. These insights reveal that while funding and collaboration are crucial, there are additional barriers related to infrastructure and policy that must be addressed.

The success of public-private partnerships, such as those seen with DNDi and Sanofi, illustrates the practical application of **push-pull incentives** and the importance of collaborative models in overcoming market failures. The challenges highlighted by healthcare professionals and policymakers underscore the need for integrated approaches that combine research, funding, and infrastructure development.

5. Case Studies and Comparative Analysis

The case studies of fexinidazole and miltefosine exemplify the potential for successful drug development through targeted research and collaboration. These examples support the theoretical framework of **push-pull incentives**, demonstrating how a combination of early-stage funding and market-based rewards can lead to successful outcomes (Kremer, 2002).

The comparative analysis reveals that regions with integrated healthcare systems and strong partnerships are more successful in drug development and distribution. This finding aligns with the **health impact investment theory**, which suggests that effective healthcare infrastructure and policy alignment are crucial for improving access and outcomes (Hotez et al., 2020).

The results of this study highlight both progress and persistent challenges in the field of NTD drug discovery and development. While funding and collaboration have improved, significant barriers remain, particularly in ensuring equitable access to treatments. The theoretical frameworks of market failure, push-pull incentives, and health impact investment provide valuable insights into the dynamics of NTD research and development. Continued efforts to enhance funding, improve infrastructure, and foster collaboration are essential for advancing the fight against NTDs and achieving more equitable health outcomes globally.

CONCLUSION

The study on drug discovery and development for Neglected Tropical Diseases (NTDs) reveals a complex landscape marked by both significant advancements and ongoing challenges.

1. **Progress and Achievements:

- **Funding Growth:** There has been a gradual increase in global funding for NTD research, reflecting some success in implementing push-pull incentives. Notable funding spikes during key global health initiatives highlight the positive impact of targeted advocacy and policy efforts.
- **Clinical Trial Success:** Advances in drug development, such as the approval of fexinidazole and the repurposing of miltefosine, demonstrate the potential of collaborative models and dedicated research efforts. These successes underscore the effectiveness of combining early-stage funding with market-based rewards.
- **Public-Private Partnerships:** Case studies of successful public-private partnerships, such as those facilitated by DNDi, illustrate the value of collaborative approaches in overcoming the limitations of market-driven R&D for NTDs.

2. **Persistent Challenges:

- **Insufficient Funding:** Despite the overall increase in funding, it remains insufficient relative to the scale of the NTD burden. The continued reliance on public and

philanthropic funding highlights ongoing market failures and the need for sustained financial commitment.

- **Clinical Trial Outcomes:** The lower success rates in clinical trials, particularly in late-phase studies, reflect the inherent difficulties in developing effective therapies for NTDs. This challenge is exacerbated by the complex nature of these diseases and the high costs of drug development.
- **Accessibility Issues:** The disparity between drug availability and affordability in low-income regions underscores persistent barriers to equitable access. High drug prices and inefficient distribution networks contribute to limited access in the most affected areas.

3. **Recommendations:

- **Enhanced Funding and Incentives:** Continued efforts to increase funding and refine push-pull incentive mechanisms are crucial. This includes exploring new funding models and ensuring that financial support is sustained and strategically allocated.
- **Strengthening Healthcare Infrastructure:** Improving healthcare infrastructure and distribution networks in endemic regions is essential for ensuring that new treatments reach those in need. Investments in healthcare systems and logistics are necessary to address the accessibility gap.
- **Fostering Collaboration:** Building on successful public-private partnerships and encouraging further collaboration between stakeholders can drive innovation and accelerate drug development. Collaborative models should be expanded to address the diverse challenges faced in NTD research.

4. **Future Directions:

- **Continued Research:** Ongoing research into new drug candidates, diagnostic tools, and treatment strategies is vital for addressing the evolving challenges of NTDs. This includes exploring innovative approaches to drug repurposing and alternative therapies.
- **Policy Alignment:** Aligning national and global health policies to support NTD drug development and access will enhance the effectiveness of existing initiatives and ensure a more coordinated response to NTDs.
- **Monitoring and Evaluation:** Regular monitoring and evaluation of drug development programs and distribution strategies will provide valuable insights into their effectiveness and inform future improvements.

  In summary, while there has been notable progress in the field of NTD drug discovery and development, significant challenges remain. Addressing these challenges requires a multi-faceted approach that combines increased funding, improved infrastructure, and strengthened collaboration. By leveraging the lessons learned from successful initiatives and continuing to invest in research and infrastructure, we can make substantial strides towards combating NTDs and improving global health outcomes.

REFERENCES

1. Hu, Jianping, Chang-Qing Tian, Mohammadali Soleimani Damaneh, Yanlian Li, Danyan Cao, Kaikai Lv, Ting Yu et al. "Structure-based discovery and development of a series of potent and selective bromodomain and extra-terminal protein inhibitors." *Journal of Medicinal Chemistry* 62, no. 18 (2019): 8642-8663.

2. Wu, Qian, Dan-Qi Chen, Lin Sun, Xia-Juan Huan, Xu-Bin Bao, Chang-Qing Tian, Jianping Hu et al. "Novel bivalent BET inhibitor N2817 exhibits potent anticancer activity and inhibits TAF1." *Biochemical Pharmacology* 185 (2021): 114435.

3. Lv, Kaikai, Weicong Chen, Danqi Chen, Jie Mou, Huijie Zhang, Tiantian Fan, Yanlian Li et al. "Rational Design and Evaluation of 6-(Pyrimidin-2-ylamino)-3, 4-dihydroquinoxalin-2 (1 H)-ones as Polypharmacological Inhibitors of BET and Kinases." *Journal of Medicinal Chemistry* 63, no. 17 (2020): 9787-9802.

4. Zhang, Huijie, Kaikai Lv, Lanping Ma, Yongliang Zhang, Ting Yu, Lin Chen, Xin Wang, Jingkang Shen, and Tao Meng. "Facile synthesis of new functionalized 3, 4-dihydro-2H-pyrroles using 2-isocyanoacetates." *Tetrahedron Letters* 61, no. 23 (2020): 151944.

5. Anway, M. D., Cupp, A. S., Uzumcu, M., & Skinner, M. K. (2005). Epigenetic Transgenerational Actions of Endocrine Disruptors and Male Fertility. Science, 308(5727), 1466–1469. https://doi.org/10.1126/science.1108190
6. Bhardwaj, A., Kaur, J., Wuest, M., & Wuest, F. (2017). In situ click chemistry generation of cyclooxygenase-2 inhibitors. Nature Communications, 8(1). https://doi.org/10.1038/s41467-016-0009-6
7. Bird, A. (2007). Perceptions of epigenetics. Nature, 447(7143), 396–398. https://doi.org/10.1038/nature05913
8. Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., & Greenberg, M. E. (1999). Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor. Cell, 96(6), 857–868. https://doi.org/10.1016/s0092-8674(00)80595-4
9. Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P. B., Shi, J., Jacobs, H. M., Kastritis, E., Gilpatrick, T., Paranal, R. M., Qi, J., Chesi, M., Schinzel, A. C., McKeown, M. R., Heffernan, T. P., Vakoc, C. R., Bergsagel, P. L., Ghobrial, I. M., Richardson, P. G., Young, R. A., . . . Mitsiades, C. S. (2011). BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc. Cell, 146(6), 904–917. https://doi.org/10.1016/j.cell.2011.08.017
10. Dey, A., Chitsaz, F., Abbasi, A., Misteli, T., & Ozato, K. (2003). The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis. Proceedings of the National Academy of Sciences, 100(15), 8758–8763. https://doi.org/10.1073/pnas.1433065100

11. Dhalluin, C., Carlson, J. E., Zeng, L., He, C., Aggarwal, A. K., Zhou, M., & Zhou, M. (1999). Structure and ligand of a histone acetyltransferase bromodomain. Nature, 399(6735), 491–496. https://doi.org/10.1038/20974
12. Dixon, M. (1953). The determination of enzyme inhibitor constants. Biochemical Journal, 55(1), 170–171. https://doi.org/10.1042/bj0550170
13. Filippakopoulos, P., Picaud, S., Mangos, M., Keates, T., Lambert, J., Barsyte-Lovejoy, D., Felletar, I., Volkmer, R., Müller, S., Pawson, T., Gingras, A., Arrowsmith, C. H., & Knapp, S. (2012). Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family. Cell, 149(1), 214–231. https://doi.org/10.1016/j.cell.2012.02.013
14. Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., Philpott, M., Munro, S., McKeown, M. R., Wang, Y., Christie, A. L., West, N., Cameron, M. J., Schwartz, B., Heightman, T. D., . . . Bradner, J. E. (2010a). Selective inhibition of BET bromodomains. Nature, 468(7327), 1067–1073. https://doi.org/10.1038/nature09504
15. Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., Philpott, M., Munro, S., McKeown, M. R., Wang, Y., Christie, A. L., West, N., Cameron, M. J., Schwartz, B., Heightman, T. D., . . . Bradner, J. E. (2010b). Selective inhibition of BET bromodomains. Nature, 468(7327), 1067–1073. https://doi.org/10.1038/nature09504
16. Fraga, M. F., Ballestar, E., Paz, M. F., Ropero, S., Setien, F., Ballestar, M. L., Heine-Suñer, D., Cigudosa, J. C., Urioste, M., Benitez, J., Boix-Chornet, M., Sanchez-Aguilera, A., Ling, C., Carlsson, E., Poulsen, P., Vaag, A., Stephan, Z., Spector, T. D., Wu, Y., . . . Esteller, M. (2005). Epigenetic differences arise during the lifetime of monozygotic twins. Proceedings of the National Academy of Sciences, 102(30), 10604–10609. https://doi.org/10.1073/pnas.0500398102
17. Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K., & Elledge, S. J. (1993). The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75(4), 805–816. https://doi.org/10.1016/0092-8674(93)90499-g
18. Heijmans, B. T., Tobi, E. W., Stein, A. D., Putter, H., Blauw, G. J., Susser, E. S., Slagboom, P. E., & Lumey, L. H. (2008). Persistent epigenetic differences associated with prenatal exposure to famine in humans. Proceedings of the National Academy of Sciences, 105(44), 17046–17049. https://doi.org/10.1073/pnas.0806560105
19. Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N., Nitsche, A., Müller, M. A., Drosten, C., & Pöhlmann, S. (2020). SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 181(2), 271-280.e8. https://doi.org/10.1016/j.cell.2020.02.052

20. Jacobson, R. H., Ladurner, A. G., King, D. S., & Tjian, R. (2000). Structure and Function of a Human TAF II 250 Double Bromodomain Module. Science, 288(5470), 1422–1425. https://doi.org/10.1126/science.288.5470.1422
21. Jang, M. K., Mochizuki, K., Zhou, M., Jeong, H., Brady, J. N., & Ozato, K. (2005). The Bromodomain Protein Brd4 Is a Positive Regulatory Component of P-TEFb and Stimulates RNA Polymerase II-Dependent Transcription. Molecular Cell, 19(4), 523–534. https://doi.org/10.1016/j.molcel.2005.06.027
22. Jones, P. A., & Takai, D. (2001). The Role of DNA Methylation in Mammalian Epigenetics. Science, 293(5532), 1068–1070. https://doi.org/10.1126/science.1063852
23. Kim, K., Doi, A., Wen, B., Ng, K., Zhao, R., Cahan, P., Kim, J., Aryee, M. J., Ji, H., Ehrlich, L. I. R., Yabuuchi, A., Takeuchi, A., Cunniff, K. C., Hongguang, H., Mckinney-Freeman, S., Naveiras, O., Yoon, T. J., Irizarry, R. A., Jung, N., . . . Daley, G. Q. (2010). Epigenetic memory in induced pluripotent stem cells. Nature, 467(7313), 285–290. https://doi.org/10.1038/nature09342
24. Kunitz, M. (1947). CRYSTALLINE SOYBEAN TRYPSIN INHIBITOR. The Journal of General Physiology, 30(4), 291–310. https://doi.org/10.1085/jgp.30.4.291
25. McGowan, P. O., Sasaki, A., D'Alessio, A. C., Dymov, S., Labonté, B., Szyf, M., Turecki, G., & Meaney, M. J. (2009). Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nature Neuroscience, 12(3), 342–348. https://doi.org/10.1038/nn.2270
26. Mertz, J. A., Conery, A. R., Bryant, B. M., Sandy, P., Balasubramanian, S., Mele, D. A., Bergeron, L., & Sims, R. J. (2011). Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proceedings of the National Academy of Sciences, 108(40), 16669–16674. https://doi.org/10.1073/pnas.1108190108
27. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997). Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth. Cell, 88(2), 277–285. https://doi.org/10.1016/s0092-8674(00)81848-6
28. Puissant, A., Frumm, S. M., Alexe, G., Bassil, C. F., Qi, J., Chanthery, Y. H., Nekritz, E. A., Zeid, R., Gustafson, W. C., Greninger, P., Garnett, M. J., McDermott, U., Benes, C. H., Kung, A. L., Weiss, W. A., Bradner, J. E., & Stegmaier, K. (2013). Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition. Cancer Discovery, 3(3), 308–323. https://doi.org/10.1158/2159-8290.cd-12-0418
29. Sanger, F., Nicklen, S., & Coulson, A. R. (1977). DNA sequencing with chain-terminating inhibitors. Proceedings of the National Academy of Sciences, 74(12), 5463–5467. https://doi.org/10.1073/pnas.74.12.5463
30. Shrestha, S., & Offer, S. M. (2016). Epigenetic Regulations of GABAergic Neurotransmission: Relevance for Neurological Disorders and Epigenetic Therapy. Medical Epigenetics, 4(1), 1–19. https://doi.org/10.1159/000444713

31. Waterland, R. A., & Jirtle, R. L. (2003). Transposable Elements: Targets for Early Nutritional Effects on Epigenetic Gene Regulation. Molecular and Cellular Biology, 23(15), 5293–5300. https://doi.org/10.1128/mcb.23.15.5293-5300.2003
32. Weaver, I. C. G., Cervoni, N., Champagne, F. A., D'Alessio, A. C., Sharma, S., Seckl, J. R., Dymov, S., Szyf, M., & Meaney, M. J. (2004). Epigenetic programming by maternal behavior. Nature Neuroscience, 7(8), 847–854. https://doi.org/10.1038/nn1276
33. Yang, Z., Yik, J. H., Chen, R., He, N., Jang, M. K., Ozato, K., & Zhou, Q. (2005). Recruitment of P-TEFb for Stimulation of Transcriptional Elongation by the Bromodomain Protein Brd4. Molecular Cell, 19(4), 535–545. https://doi.org/10.1016/j.molcel.2005.06.029
34. Yung-Chi, C., & Prusoff, W. H. (1973). Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochemical Pharmacology, 22(23), 3099–3108. https://doi.org/10.1016/0006-2952(73)90196-2
35. Yusuf, S., Sleight, P., Pogue, J., Bosch, J., Davies, R., & Dagenais, G. (2000). Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients. New England Journal of Medicine, 342(3), 145–153. https://doi.org/10.1056/nejm200001203420301